LLY
Eli Lilly and Company
LLY has the edge over XNCR overall, supported by stronger fundamentals and lower modeled downside.
XNCR
Xencor, Inc.
XNCR trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
XNCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Strong |
XNCR's revenue and balance sheet are currently strong, but its profitability and cash flow are weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
XNCR PE Valuation
XNCR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
XNCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect XNCR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over XNCR on earnings quality, reporting a profit while its opponent remains loss making.
XNCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.59 | +$0.13 |
| Q2 2026 | -$2.17 | +$0.19 |
| Q1 2026 | -$2.29 | +$0.75 |
| Q4 2025 | -$1.24 | +$2.34 |
| Q3 2025 | -$1.72 | +$1.70 |
| Q2 2025 | -$2.36 | +$0.74 |
| Q1 2025 | -$3.04 | -$0.66 |
| Q4 2024 | -$3.58 | -$1.38 |
XNCR is still losing money, but far less than before: $1.59 per share over the past year, against $3.58 at its worst in late 2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over XNCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over XNCR on profitability, with a higher operating margin.
XNCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $116.5M | +455% |
| Q2 2026 | $51.2M | +17% |
| Q1 2026 | $4.5M | -86% |
| Q4 2025 | $28.2M | -47% |
| Q3 2025 | $21M | +18% |
| Q2 2025 | $43.6M | +82% |
| Q1 2025 | $32.7M | +105% |
| Q4 2024 | $52.8M | +3.6% |
XNCR's revenue is recovering but still below its 2021 peak: $117M last quarter, up 455% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +246 points |
| Q2 2026 | -72% | +3.7 points |
| Q1 2026 | -1724% | -1592 points |
| Q4 2025 | -190% | -165 points |
| Q3 2025 | -226% | +84 points |
| Q2 2025 | -76% | +156 points |
| Q1 2025 | -132% | +210 points |
| Q4 2024 | -25% | +29 points |
XNCR's operating margin was 20% last quarter, up 246 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over XNCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XNCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $838K | +$31.8M |
| Q2 2026 | -$56.2M | -$19.4M |
| Q1 2026 | -$68.2M | -$50.6M |
| Q4 2025 | -$52.9M | -$1.4M |
| Q3 2025 | -$31M | -$1.6M |
| Q2 2025 | -$36.8M | +$33.6M |
| Q1 2025 | -$17.7M | +$39.3M |
| Q4 2024 | -$51.5M | -400% |
XNCR has burned cash in most quarters: −$176M over the past year, against −$137M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over XNCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
XNCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +2.5M shares |
| 1 year | +5.3% | +3.9M shares |
| 3 years | +29% | +17.7M shares |
| 5 years | +34% | +20M shares |
| Available history | +34% | +19.9M shares |
XNCR has 78M diluted shares, up 5.3% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
XNCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -0.9x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -0.8x | Net Cash |
| Q4 2021 | -2.8x | Net Cash |
| Q4 2019 | -2.8x | Net Cash |
XNCR has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
XNCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 81.4 | Overbought |
| Stochastic | 85.8 | Overbought |
XNCR's weekly RSI is 81 (overbought) and its Stochastic is 86 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
XNCR PE vs Healthcare Sector
| Metric | XNCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XNCR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
XNCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.1 | 36% above |
| 20 week MA | $24.3 | 57% above |
| 50 week MA | $17.5 | 118% above |
| 100 week MA | $15.0 | 154% above |
| 200 week MA | $19.0 | 101% above |
XNCR has climbed back above all five of its weekly moving averages, and it's now 101% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
XNCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $46.1 | +30% |
| 2021 | $46.1 | $40.7 | -12% |
| 2022 | $40.7 | $26.1 | -36% |
| 2023 | $26.1 | $21.2 | -19% |
| 2024 | $21.2 | $24.3 | +14% |
| 2025 | $24.3 | $15.2 | -37% |
| 2026 YTD | $15.2 | $38.1 | +151% |
XNCR has the edge over LLY on returns for 2026, with the stronger performance.